ArticleCureus2026
Triple Infections With Campylobacter coli, Cytomegalovirus, and SARS-CoV-2 in a Lymphoma Patient Treated With Epcoritamab.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant lymphoma is a common hematological malignancy, characterized by immunocompromise due to lymphocytic dysfunction. Chemoimmunotherapy for malignant lymphoma, including corticosteroids, rituximab (R), and Bruton's tyrosine kinase inhibitors, depletes normal lymphocytes and disrupts lymphocyte function. Muchmore, various novel treatment modalities, including antibody-drug conjugates, chimeric antigen receptor T cell (CAR-T) therapy, and bispecific T-cell engager (BiTE) antibody treatments such as epcoritamab, are all utilized to target the patient's own B lymphocytes targeted via mature B cell molecules. The latest anti-lymphoma therapy, epcoritamab, can promote CD3+ T lymphocytes to attack CD20+ normal B lymphocytes and lymphoma cells. Consequently, heavily treated lymphoma patients may experience compromised lymphocyte function. We treated a case of relapsed malignant lymphoma, infected with triple infections, Campylobacter coli, Cytomegalovirus, and SARS-CoV-2, during treatment with epcoritamab after standard chemoimmunotherapies, including R-cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP), and R-bendamustine. After three cycles of epcoritamab therapy, the patient developed moderate COVID-19 pneumonia requiring oxygen therapy. Concurrently, he had a bloodstream infection with Campylobacter coli due to Campylobacter coli enterocolitis and Cytomegalovirus antigenemia. His treatment for infections included remdesivir, meropenem, and ganciclovir. By day 12, his infectious diseases improved, and he was discharged in complete recovery. However, he had persistent SARS-CoV-2 viral shedding for six weeks or longer. Epcoritamab can demonstrate long-standing B-cell depletion; however, a long-term influence on T cells is still elusive. This case suggested that we should pay special attention to patients with B-cell manipulating therapy including R, CAR-T, and BiTEs such as epcoritamab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.